Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer

In order to explore the efficacy of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer, 100 patients with triple negative breast cancer who met the screening criteria were divided into two groups according to the random number table method. One group was treated with albumin bound paclitaxel and cisplatin chemotherapy as the conventional chemotherapy group, and the other group was treated with anlotinib Hydrochloride Capsules on the basis of the conventional chemotherapy group. Both groups were treated for 6 cycles. After half a year of treatment, compared with the conventional chemotherapy group, the Orr and CBR of the combined drug treatment group were significantly increased, and the levels of bone sialoprotein (BSP), prolactin (PRL), insulin like growth factor -1 (IGF-1) and angiopoietin-2 (Ang-2) were significantly decreased, the difference was statistically significant. There were no serious adverse events in the two groups during the treatment, and there was no significant difference in the incidence of adverse reactions between the two groups; The deadline for follow-up of all patients was June 2023, and the followup time was 8-36 months. The medianProgression-free survival (PFS) of patients in the conventional chemotherapy group was 29.38 months (95% CI: 26.918-31.842), and the median PFS of patients in the combined drug treatment group was 33.72 months (95% CI: 32.417-35.023). There was a statistically significant difference in survival between the two groups (Log rank = 4.072, p = 0.044). The curative effect of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer is significant, which can effectively reduce the level of relevant serum factors, has high safety, and is helpful to improve the survival of patients.